- Home
- VIVS vs PPBT Comparison
VIVS vs PPBT Comparison
Compare VIVS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | PPBT |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.4M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VIVS | PPBT |
|---|---|---|
| Price | $0.28 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 5.9M | 28.2K |
| Earning Date | 06-04-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,603,000.00 | N/A |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.82 | N/A |
| 52 Week Low | $0.26 | $0.41 |
| 52 Week High | $5.30 | $5.18 |
Technical Indicators
Market Signals| Indicator | VIVS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 27.57 | 56.41 |
| Support Level | N/A | $1.38 |
| Resistance Level | $0.58 | $1.85 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 4.18 | 87.02 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.